These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Nephrectomy in metastatic renal cell carcinoma. Campbell SC; Flanigan RC; Clark JI Curr Treat Options Oncol; 2003 Oct; 4(5):363-72. PubMed ID: 12941196 [TBL] [Abstract][Full Text] [Related]
3. Multi-modal treatment for metastatic renal cancer: the role of surgery. Russo P World J Urol; 2010 Jun; 28(3):295-301. PubMed ID: 20364382 [TBL] [Abstract][Full Text] [Related]
4. Integration of surgery and systemic therapy for renal cell carcinoma. Kenney PA; Wood CG Urol Clin North Am; 2012 May; 39(2):211-31, vii. PubMed ID: 22487764 [TBL] [Abstract][Full Text] [Related]
5. The evolving role of cytoreductive surgery for metastatic renal cell carcinoma. Chaudhary UB; Hull GW Oncology (Williston Park); 2003 May; 17(5):701-5; discussion 705-6, 711-2. PubMed ID: 12800795 [TBL] [Abstract][Full Text] [Related]
6. Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis. Bex A; Haanen JB; Vyth-Dreese FA; Horenblas S; de Gast GC Urol Int; 2008; 80(4):367-71. PubMed ID: 18587246 [TBL] [Abstract][Full Text] [Related]
7. Clinical study of brain metastasis of renal cell carcinoma. Harada Y; Nonomura N; Kondo M; Nishimura K; Takahara S; Miki T; Okuyama A Eur Urol; 1999 Sep; 36(3):230-5. PubMed ID: 10450008 [TBL] [Abstract][Full Text] [Related]
8. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825 [TBL] [Abstract][Full Text] [Related]
9. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy. Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737 [TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106 [TBL] [Abstract][Full Text] [Related]
11. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645 [TBL] [Abstract][Full Text] [Related]
12. Metastatic renal cell carcinoma risk according to tumor size. Thompson RH; Hill JR; Babayev Y; Cronin A; Kaag M; Kundu S; Bernstein M; Coleman J; Dalbagni G; Touijer K; Russo P J Urol; 2009 Jul; 182(1):41-5. PubMed ID: 19450840 [TBL] [Abstract][Full Text] [Related]
14. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma. Jeon SH; Chang SG; Kim JI Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624 [TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort. Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942 [TBL] [Abstract][Full Text] [Related]
16. Characteristics and prognosis of chromophobe non-metastatic renal cell carcinoma: a multicenter study. Lee WK; Byun SS; Kim HH; Rha KH; Hwang TK; Sung GT; Lee W; Lim JS; Jeong YB; Kwon TG Int J Urol; 2010 Nov; 17(11):898-904. PubMed ID: 20969636 [TBL] [Abstract][Full Text] [Related]
17. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278 [TBL] [Abstract][Full Text] [Related]
18. New treatments for metastatic kidney cancer. Mancuso A; Sternberg CN Can J Urol; 2005 Feb; 12 Suppl 1():66-70; discussion 105. PubMed ID: 15780170 [TBL] [Abstract][Full Text] [Related]
19. The role of cytoreductive nephrectomy in the era of molecular targeted therapy. Polcari AJ; Gorbonos A; Milner JE; Flanigan RC Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114 [TBL] [Abstract][Full Text] [Related]
20. Renal cell carcinoma and brain metastasis: Questioning the dogma of role for cytoreductive nephrectomy. Daugherty M; Daugherty E; Jacob J; Shapiro O; Mollapour M; Bratslavsky G Urol Oncol; 2019 Mar; 37(3):182.e9-182.e15. PubMed ID: 30528396 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]